The administration of intravesical chemotherapy or BCG often can prolong the progression-free interval after initial transurethral resection in select bladder cancer (BCa) patients. However, 60% of these patients will recur and up to 30% of patients with recurrent BCa will progress and succumb to their disease over a 15 year period, while another 50% will cystectomy in an attempt to control their disease. Thus better therapeutic strategies are needed for patients who have failed intravesical therapy. In this article, we report the treatment of a 91-year-old man with NMIBC with high-risk features that had failed multiple intravesical therapies.
Urology case reports. 2017 Jun 08*** epublish ***
Jeffrey Huang, John Schisler, Hing C Wong, Charles J Rosser, Joseph Sterbis
University of Hawaii Cancer Center, Clinical & Translational Research Program, Honolulu, HI, 96813, USA., Tripler Army Medical Center, Department of Urology, Honolulu, HI, 96859, USA., Altor BioScience Corporation, 2810 North Commerce Parkway, Miramar, FL 33025, USA.